CBER research update
Executive Summary
FDA's Biological Response Modifiers Advisory Committee will meet June 9 by teleconference to hear updates on research projects being conducted in the Center for Biologics Evaluation & Research's Division of Cellular & Gene Therapies. The meeting will be held from 1 p.m. to 3:30 p.m. and an audio link to the meeting will be available at the National Institutes of Health campus (building 29, room 1A09) in Bethesda, Md...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.